It’s hard to find a silver lining following news that sends a stock crashing 84.5 percent in one day. However, following devastating news that the Phase III RESOLVE trial of its RSV vaccine failed to deliver the desired results, Novavax, Inc. NVAX 10.82% shareholders are looking for any reason to stay positive on the decimated stock.
According to CNBC’s Meg Tirrell, the company is still hopeful on several fronts. First, Novavax claims it will be testing a vaccine for Zika virus on non-human primates “very soon.” In addition, the company is simply looking for funding for its Ebola vaccine, which it claims is “the best.”
Understandably, Wall Street is skeptical. The RSV news was followed by a string of downgrades and aggressive price target reductions among analysts covering Novavax’s stock.
Wedbush analyst Heather Behanna downgraded Novavax from Outperform to Neutral and lowered the firm’s price target from $14 to $2. It terms of the future, Behanna believes “one option could be an adaptive design to account for variability in RSV or a focus on cumulative data over more than one season.” Wedbush is not factoring these possibilities into its current model.
Citi analyst Joel Beatty also downgraded the stock from Buy to Neutral and slashed his price target from $12 to $1.50. City also greatly reduced its probability of success for Novavax’s maternal RSV vaccine from 60 percent to 20 percent and for its older adult RSV vaccine from 70 percent to 10 percent. Novavax optimists might take comfort in the fact that 10–20 percent is a far cry from zero.
Finally, Piper Jaffray analyst Edward Tenthoff downgraded Novavax from Overweight to Neutral and cut his price target from $14 to $1. Tenthoff noted…
Click here to continue reading
Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!
